Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells
JO Richards, S Karki, GA Lazar, H Chen, W Dang… - Molecular cancer …, 2008 - AACR
The contribution of Fc-mediated effector functions to the therapeutic efficacy of some
monoclonal antibodies has motivated efforts to enhance interactions with Fcγ receptors …
monoclonal antibodies has motivated efforts to enhance interactions with Fcγ receptors …
Fc Optimization of Therapeutic Antibodies Enhances Their Ability to Kill Tumor Cells In vitro and Controls Tumor Expansion In vivo via Low-Affinity Activating Fcγ …
JB Stavenhagen, S Gorlatov, N Tuaillon, CT Rankin… - Cancer research, 2007 - AACR
Monoclonal antibodies (mAb) are widely used in the treatment of non-Hodgkin's lymphoma
and autoimmune diseases. Although the mechanism of action in vivo is not always known …
and autoimmune diseases. Although the mechanism of action in vivo is not always known …
Fc-receptor interactions regulate both cytotoxic and immunomodulatory therapeutic antibody effector functions
DJ DiLillo, JV Ravetch - Cancer immunology research, 2015 - AACR
Antibodies are now recognized as key therapeutic tools to combat most forms of malignancy.
Although the first wave of therapeutic antibodies that emerged over two decades ago directly …
Although the first wave of therapeutic antibodies that emerged over two decades ago directly …
Harnessing Fc receptor biology in the design of therapeutic antibodies
P Sondermann, DE Szymkowski - Current opinion in immunology, 2016 - Elsevier
Highlights•The antibody Fc domain engages immune-activating, inhibitory, and homeostatic
Fc receptors.•Fc domains are largely unaltered in existing therapeutic antibodies, whether to …
Fc receptors.•Fc domains are largely unaltered in existing therapeutic antibodies, whether to …
Engineered antibody Fc variants with enhanced effector function
GA Lazar, W Dang, S Karki, O Vafa… - Proceedings of the …, 2006 - National Acad Sciences
Antibody-dependent cell-mediated cytotoxicity, a key effector function for the clinical efficacy
of monoclonal antibodies, is mediated primarily through a set of closely related Fcγ …
of monoclonal antibodies, is mediated primarily through a set of closely related Fcγ …
Fcγ receptors and immunomodulatory antibodies in cancer
The discovery of both cytotoxic T lymphocyte-associated antigen 4 (CTLA4) and
programmed cell death protein 1 (PD1) as negative regulators of antitumour immunity led to …
programmed cell death protein 1 (PD1) as negative regulators of antitumour immunity led to …
FcγRIIIb restricts antibody-dependent destruction of cancer cells by human neutrophils
LW Treffers, M Van Houdt, CW Bruggeman… - Frontiers in …, 2019 - frontiersin.org
The function of the low-affinity IgG-receptor FcγRIIIb (CD16b), which is uniquely and
abundantly expressed on human granulocytes, is not clear. Unlike the other Fcγ receptors …
abundantly expressed on human granulocytes, is not clear. Unlike the other Fcγ receptors …
[HTML][HTML] Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies
Y Bulliard, R Jolicoeur, M Windman… - The Journal of …, 2013 - ncbi.nlm.nih.gov
Fc γ receptor (FcγR) coengagement can facilitate antibody-mediated receptor activation in
target cells. In particular, agonistic antibodies that target tumor necrosis factor receptor …
target cells. In particular, agonistic antibodies that target tumor necrosis factor receptor …
FcγR: the key to optimize therapeutic antibodies?
The binding of IgG to receptors for the Fc region of IgG (FcγR) is a critical step for the
initiation and the control of effector immune functions. Activating FcγR induce antibody …
initiation and the control of effector immune functions. Activating FcγR induce antibody …
FcγR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities
F Nimmerjahn, S Gordan, A Lux - Trends in immunology, 2015 - cell.com
Given the widespread use of antibodies of the immunoglobulin G (IgG) class as cytotoxic,
immunomodulatory, and neutralizing agents in the therapy of malignant, infectious, and …
immunomodulatory, and neutralizing agents in the therapy of malignant, infectious, and …